Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55803 | 1.00 | CA1 (0.43) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL2855857 | 1.00 | CA1 (0.43) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL93201 | 1.00 | CA1 (0.43) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL2858733 | 1.00 | CA1 (0.43) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL2862726 | 1.00 | CA1 (0.43) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL68307 | 1.00 | CA1 (0.43) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL157306 | 1.00 | CA1 (0.43) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL77312 | 1.00 | CA1 (0.43) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL2861027 | 1.00 | CA1 (0.43) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL104986 | 1.00 | CA1 (0.43) | CA1CA2CA9LPAR3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2921499-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-7758932-B2 | Liquid crystal display device and display apparatus | RICOH COMPANY, LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-1972676-B1 | Liquid crystal alignment film composition, liquid crystal device and display apparatus | RICOH KK (JP) | 2010-03-10 | — | — | EP | disclosed |
| US-7658979-B2 | Liquid crystal alignment film composition, liquid crystal device and display apparatus | RICOH COMPANY, LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20080305280-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY APPARATUS | RICOH COMPANY, LTD. | 2008-12-11 | — | — | US | disclosed |
| US-20080231785-A1 | LIQUID CRYSTAL ALIGNMENT FILM COMPOSITION, LIQUID CRYSTAL DEVICE AND DISPLAY APPARATUS | RICOH COMPANY, LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1972676-A1 | Liquid crystal alignment film composition, liquid crystal device and display apparatus | Ricoh Company, Ltd. (JP) | 2008-09-24 | — | — | EP | disclosed |
| WO-1999049865-A1 | USE OF PLATELET ACTIVATING FACTOR (PAF) INHIBITORS TO INHIBIT IL-5 INDUCED EOSINOPHIL ACTIVATION OR DEGRANULATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5334583-A | Topical administrable viricides | CIBA-GEIGY CORP. (US) | 1994-08-02 | — | — | US | disclosed |
| US-5189017-A | Administering salt of muramyl tripeptide derivative | CIBA-GEIGY CORPORATION (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0102319-B1 | PROPHYLACTIC AND THERAPEUTIC USE OF MURAMYL PEPTIDES AND THEIR ANALOGUES AGAINST VIRAL INFECTIONS | CIBA-GEIGY AG (CH) | 1987-08-19 | — | — | EP | disclosed |
| EP-0102319-A1 | Prophylactic and therapeutic use of muramyl peptides and their analogues against viral infections | CIBA-GEIGY AG (CH) | 1984-03-07 | — | — | EP | disclosed |
| US-4423038-A | Phosphoryl compounds, pharmaceutical preparations containing such compounds, and their use | CIBA-GEIGY CORPORATION (US) | 1983-12-27 | — | — | US | disclosed |
| EP-0056992-A1 | Phosphorylated derivatives, pharmaceutical compositions containing such derivatives, and their use | CIBA-GEIGY AG (CH) | 1982-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | CA1 3539/4885CA2 3194/4885CA9 2597/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | CA1 4486/4885CA2 4503/4885CA9 3880/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | CA1 4503/4885CA2 4489/4885CA9 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.